cropped color_logo_with_background.png

Clinical Trial Finder

Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma

Study Purpose

The purpose of this pilot study is to determine the safety, tolerability, and the maximum tolerated dose intranasal administration of temozolomide (TMZ) as a single agent in Treatment on the patients with GBM. Intranasal administration is a new method of treating brain tumours for the direct administration of drugs, inhibitors or viruses, with minimal involvement of the BBB. The investigators know the orally prescribed standard chemotherapy temozolomide (TMZ) is widely used to treat glioma tumours. Received evidence of safety and efficacy in a full cycle of preclinical trials (on GLP Standart) and tests of calculated doses of intranasal administration of TMZ in healthy volunteers. Intranasal administration of temozolomide is considered as GBM therapy, which provides direct access to a therapeutic dose of the drug into the brain (to the neoplastic process) with low toxicity

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

 No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

 Interventional
Eligible Ages 21 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Informed consent signed.
  • - 21 years or older.
  • - Histologically confirmed the diagnosis of Grade 4 astrocytic tumour, which includes glioblastoma, giant cell glioblastoma, gliosarcoma, and glioblastoma with oligodendroglial components.
  • - The availability of histological material for the possibility of revising histological verification.
  • - IDH 1 Mutation and IDH2 Mutation are not taken into account when enrolling in that study.
  • - MGMT promoter methylation MUST BE CONFIRMED.
  • - Must have a Karnofsky performance status of ≥ 70% and the ability to use intranasal administration.
  • - Sexually active fertile subjects (male and female) must agree to use accepted methods of contraception during the course of the study and for 3 months after the last intranasal administration of Temozolomide.
  • - Female subjects of childbearing potential must have a negative pregnancy test at screening.
  • - Must be capable of understanding and complying with the protocol requirements.

Exclusion Criteria:

  • - History of hypersensitivity to TMZ or any of its excipients.
  • - The subject has had major surgery within 28 days prior to starting study treatment, or had non-water-tight dural closure during previous surgery, or has unhealed wounds from previous surgery.
  • - The subject has inherited bleeding diathesis or coagulopathy with the risk of bleeding.
  • - The subject is pregnant or breastfeeding.
  • - The subject suffered a stroke according to the results of the first MRI upon admission.
  • - Anti-cancer Agents: Subjects who are currently receiving other anticancer agents are not eligible.
Subjects must have fully recovered from the effects of prior chemotherapy (haematological and bone marrow suppression effects), generally at least 3 weeks from the most recent administration (6 weeks for nitrosoureas). Subjects may not have received more than 1 cycle of Irinotecan and Temozolomide as previous relapse therapy. - Subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

 NCT04091503
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

 Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

 Center Trials & Treatment Europe
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

 N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

 Other
Overall Status Completed
Countries Bosnia and Herzegovina, Bulgaria, Georgia
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

 Glioma, Malignant, Gliosarcoma, Astrocytoma of Brain
Additional Details

The investigators are trying to evaluate a clinically potentially effective intranasal way of delivering TMZ to the brain, taking into account the anatomical structure of os ethmoidal. The most important factor in the effectiveness of the drug is the achievement of an adequate amount of the active agent in its unbound state with albumin on the blood of a patient and the exposure time to the tumour process. Failure to comply with this requirement (difficulties in overcoming the BBB) was identified as the main obstacle to the successful treatment of all types of brain tumours. Translation to improved clinical outcomes in a patient with GBM has not yet been realized. The investigators will use modified temozolomide (without changing the chemical formula) to exclude as much as possible Anosmia, Hyposmia and other violation of the identification of odours with participants.

Arms & Interventions

Arms

Active Comparator: Intranasal Modified Temozolomide 75 mg/M2 per day

75 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)

Active Comparator: Intranasal Modified Temozolomide 150 mg/M2 per day

150 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)

Active Comparator: Intranasal Modified Temozolomide 200 mg/M2 per day

200 mg/M2 per day Intranasal Modified Temozolomide administration of within 5 days per week (max: 30 days)

Interventions

Drug: - Intranasal Modified Temozolomide

Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.). After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Central Contact, Banja Luka, Bosnia and Herzegovina

Status

Address

Central Contact

Banja Luka, , 78000

Central Contact, Plovdiv,, Bulgaria

Status

Address

Central Contact

Plovdiv,, , 4004

Central Contact, Tbilisi, Georgia

Status

Address

Central Contact

Tbilisi, , 0008

Powered By